Risk Factors Analysis of Severe Liver Injury Induced by Statins

Author:

Su Feng-yun1,Li Wen-hua2,Zhao Xu-dong3,Han Qian4,Xu Xin5,Geng Tao1

Affiliation:

1. Department of Pharmacy, The Second Affiliated Hospital of Shandong First Medical University, Tai’an, China

2. Department of Orthopedics, The Second Affiliated Hospital of Shandong First Medical University, Tai’an, China

3. Department of Obstetrics and Gynecology, The Affiliated Tai’an City Central Hospital of Qingdao University, Qingdao, China

4. Department of Respiratory, The Second Affiliated Hospital of Shandong First Medical University, Tai’an, China

5. Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, Tai’an, China

Abstract

AbstractThe aim of this study is to report the risk factors of severe statin induced liver injury (SILI). From the database of Shandong ADR Monitoring Center and Outpatients and inpatients in our hospital, SILI cases reported from 2013 to 2021 were extracted and screened. The diagnostic criteria of SILI, the inclusion and exclusion criteria of severe and general SILI were established separately. After the SILI cases were selected and confirmed, the socio-demographic and clinical characteristics were collected. Single factor chi-square test and multi-factor unconditional logistic regression analysis were used to analyze the influencing factors of severe SILI. From 1391 reported cases, 1211 met SILI diagnostic criteria, of which 157 were severe SILI and 964 were general SILI. Univariate analysis showed that age, drug combination, statin category were the influencing factors of severe SILI (p<0.1). Multivariate logistic analysis showed that drug combination and statin category were the influencing factors of severe SILI (p<0.05). Atorvastatin caused the most serious SILI, and its risk is 1.77 times higher than rosuvastatin. The serious SILI risk of drug combination was 2.08 times higher than statin alone. The patient with these factors should be monitored intensively during clinical treatment, to ensure their medication safety.

Funder

Shandong Adverse Drug Reaction Monitoring Center Project

Publisher

Georg Thieme Verlag KG

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,General Medicine,Endocrinology, Diabetes and Metabolism

Reference22 articles.

1. Awareness, treatment, control, and determinants of dyslipidemia among adults in China;S Opoku;Sci Rep,2021

2. Epidemiology of dyslipidemia in Chinese adults: meta-analysis of prevalence, awareness, treatment, and control;Y Huang;Popul Health Metr,2014

3. Interpretation of the evidence for the efficacy and safety of statin therapy;R Collins;Lancet,2016

4. [Experts consensus of the evaluation on the statin drugs safty];Working Group of the Evaluation on the Safety of S;Zhonghua Xin Xue Guan Bing Za Zhi,2014

5. An assessment by the Statin Liver Safety Task Force: 2014 update;H Bays;J Clin Lipidol,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3